The Artemis Fund
VC Fund
Houston, United States
The Artemis Fund is a VC fund in Houston focused on Software and E-Commerce. The Artemis Fund invests in female-founded, tech-enabled companies that help people build wealth and allow people to care for their families and communities in a more sustainable way.
- Total investments:
- 45
- Last investment:
- Lead investor:
- 22%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries The Artemis Fund invests in
Stages The Artemis Fund invests in
Countries The Artemis Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1M–$6M
- Pre-Seed
- $1.1M–$3.3M
- Series A
- $7.3M–$15M
Investment Focus
Industry
- Software 5 (11%)
- E-Commerce 5 (11%)
- Health Care 5 (11%)
- Apps 3 (7%)
- FinTech 3 (7%)
Stage
- Seed 18 (40%)
- Series A 6 (13%)
- Pre-Seed 4 (9%)
- Series B 2 (4%)
- Series D 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Adrienne Mangual
VP of Finance & Operations
|
VP of Finance & Operations | Total investments: 0 | Find email | |
Diana Murakhovskaya
General Partner & Co-Founder
|
General Partner & Co-Founder | Total investments: 5 | Find email | |
Juliette Richert
Senior Analyst
|
Senior Analyst | Total investments: 0 | Find email | |
Stephanie Campbell
General Partner
|
General Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Salvo Health
|
Salvo is emerging as the leader in helping GI providers leap into a hybrid-care vision of the future of medicine, providing brick & mortar clinics with an easy to implement continuous care platform that saves time, increases revenue and improves patient outcomes.The company has announced agreements with 771 GI’s, representing 15% of allindependent GI’s in the US, to deploy wraparound care for their clinic patients. Included in its customers are five of the largest GI practices in the country, together seeing over 1.1 million GI patients a year. Salvo provides the tech and care delivery for modern, interdisciplinary care to treat chronic conditions that have surged in cost and prevalence: --IBS and IBD (over 40M affected) -- GERD and Celiac (over 50M affected) --MASH/MASLD, what was previously called “fatty liver disease” (over 80M) --Obesity (over 100M) The care benefits patients (76% of patients reported improved symptoms, five accepted medical conference abstracts on outcomes), generates incremental profit for practices (over $2M EBITDA improvement for a 100 GI practice), and reduces total healthcare costs (79% drop in GI-related ER utilization). | $8.5M / Series A / Jan 22, 2026 | |
Avela Health
|
Avela Health offers remote autism diagnostic evaluations and personalized therapy for neurodiverse children and families. | $6.4M / Seed / Jan 12, 2026 | |
Brij
|
Brij is a software platform that bridges the offline and online for omnichannel brands. | $8M / Venture - Series Unknown / Jun 24, 2025 | |
Gemist
|
Gemist is the first-ever D2C custom jewelry company focused on the way millennials engage jewelry. We have made it easy to custom design jewelry through our branding, technology and namely our unique home “Try-and-Buy” experience. | $6M / Seed / Jun 24, 2025 | |
|
Salvo Health
|
Salvo is emerging as the leader in helping GI providers leap into a hybrid-care vision of the future of medicine, providing brick & mortar clinics with an easy to implement continuous care platform that saves time, increases revenue and improves patient outcomes.The company has announced agreements with 771 GI’s, representing 15% of allindependent GI’s in the US, to deploy wraparound care for their clinic patients. Included in its customers are five of the largest GI practices in the country, together seeing over 1.1 million GI patients a year. Salvo provides the tech and care delivery for modern, interdisciplinary care to treat chronic conditions that have surged in cost and prevalence: --IBS and IBD (over 40M affected) -- GERD and Celiac (over 50M affected) --MASH/MASLD, what was previously called “fatty liver disease” (over 80M) --Obesity (over 100M) The care benefits patients (76% of patients reported improved symptoms, five accepted medical conference abstracts on outcomes), generates incremental profit for practices (over $2M EBITDA improvement for a 100 GI practice), and reduces total healthcare costs (79% drop in GI-related ER utilization). | $4.7M / Seed / Feb 10, 2025 | |
SimpliFed
|
SimpliFed is a healthcare technology company that provides virtual maternal care focused on breastfeeding and baby feeding support for families. It offers a telehealth platform that connects parents with certified lactation and baby-feeding specialists, delivering personalized, evidence-based care from pregnancy through the postpartum period. Theplatform includes services such as feeding guidance, remote monitoring, mental health screenings, and ongoing support to improve maternal and infant health outcomes. SimpliFed works closely with healthcare providers and health plans, integrating its services into existing care systems to enhance access and continuity of care. Its approach emphasizes inclusive, judgment-free support, helping parents make informed decisions about feeding methods while addressing both physical and emotional well-being. | $4M / Seed / Feb 04, 2025 | |
RollCredits
|
RollCredits offers a suite of software solutions designed to enhance the productivity of creative professionals. The platform focuses on streamlining content creation processes, enabling users to efficiently manage budgets, track expenses, and handle invoices with features like petty cash cards that offer 1% cashback. Aimed at simplifying theadministrative side of content production, RollCredits provides tools to compare actual spending against budgets, ensuring financial oversight and saving users both time and money. The service emphasizes secure data handling, with measures such as automatic HTTPS for web applications, to protect sensitive information during online transactions. | $3M / Seed / Jul 01, 2024 | |
MaxRetail
|
Max Retail helps independent retailers and brands sell their unsold inventory through its market network that includes B2B, B2C and liquidation channels. | $15M / Series A / Apr 29, 2024 | |
|
Gemist
|
Gemist is the first-ever D2C custom jewelry company focused on the way millennials engage jewelry. We have made it easy to custom design jewelry through our branding, technology and namely our unique home “Try-and-Buy” experience. | Seed / Feb 20, 2024 | |
Builders Patch
|
We work with builders to manage their deal from acquisition to finance on one collaborative platform that allows all partners to access all information, analytics in real time. We help raise construction finance efficiently and easily through our marketplace. | Seed / Jan 20, 2024 | |
| See all 45 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does The Artemis Fund invest in?
The Artemis Fund invests primarily in Software, E-Commerce and Health Care startups, most often at Seed and Series A stage. Most of the 45 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is The Artemis Fund's check size?
The Artemis Fund typically joins rounds of $1M–$6M at Seed, $1.1M–$3.3M at Pre-Seed and $7.3M–$15M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds The Artemis Fund participates in.
How do I contact The Artemis Fund?
Public channels for The Artemis Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at The Artemis Fund?
The team at The Artemis Fund includes Adrienne Mangual (VP of Finance & Operations), Diana Murakhovskaya (General Partner & Co-Founder) and Juliette Richert (Senior Analyst). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
